An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
Clin Exp Rheumatol
; 36(1): 88-93, 2018.
Article
em En
| MEDLINE
| ID: mdl-28850020
ABSTRACT
OBJECTIVES:
The aim of this study was to investigate the relationship between serum infliximab (IFX) levels and changes of RF and ACPA levels in patients with rheumatoid arthritis (RA).METHODS:
Enzyme-linked immunosorbent assays (ELISA) [Promonitor® IFX R1 (version 2) (Progenika Biopharma, Spain)] were used to measure drug levels and antidrug-antibodies (ADAb) in IFX RA-treated patients (n=19). Disease activity was assessed using DAS28. IgM rheumatoid factor (RF) and IgM, IgA and IgG anti-cyclic citrullinated peptide (ACPA) were determined through ELISA.RESULTS:
A significant decrease in RF (p=0.01), ACPA IgG (p=0.007), IgM (p=0.01) and IgA (p=0.03) was observed in patients presenting adequate levels of serum IFX. No significant changes to RF or ACPA were observed in patients with undetectable IFX.CONCLUSIONS:
Data from this study support the hypothesis that the anti-TNF antagonist IFX downregulates autoantibody levels in RA patients when IFX levels are detectable. Larger-scale studies need to be performed to establish RF and ACPA presence as therapeutic response predictive factors.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos Cíclicos
/
Artrite Reumatoide
/
Fator Reumatoide
/
Antirreumáticos
/
Infliximab
/
Anticorpos Antiproteína Citrulinada
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article